Orphazyme delays annual report again after striking deal with Kempharm

Orphazyme has provided yet another new date for the release of its 2021 annual report, following the biotech firm’s deal to sell its business to Kempharm. Almost three months have passed since the original release date.

Photo: Nikolaj Skydsgaard/Reuters/Ritzau Scanpix

Orphazyme, a listed company in Denmark that has been restructuring since March, has postponed its annual report for 2021 yet again, a company press release states.

This follows the Sunday announcement that the Danish firm has come to a binding agreement with US-based Kempharm, entailing the sale of all substantial Orphazyme assets and business activities.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs